Navigation Links
Novavax Named Biotechnology Firm of the Year by Tech Council of Maryland
Date:5/11/2011

ROCKVILLE, Md., May 11, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has been named Biotechnology Firm of the Year by the Tech Council of Maryland (TCM), the largest technology trade group serving the advanced technology and biotechnology communities of Maryland.  Novavax was recognized as the firm that best exemplifies the spirit of the Maryland biotechnology community and for its presence and leadership in Maryland.

The criteria for selection as biotechnology firm of the year include achieving significant and measurable success, contributing to the advancement of biosciences through cutting-edge research and development, executing a successful growth strategy, and helping to foster a vibrant biotech community.

Stanley Erck, President and Chief Executive Officer of Novavax, stated:  "We are honored to be recognized by the Tech Council of Maryland for our work to develop innovative vaccines to prevent the spread of infectious diseases worldwide.  We have made substantial clinical and corporate progress in the past year and are now in a very strong position to pursue the development of vaccines derived from our unique virus-like particle technology.  My colleagues and I are particularly grateful to the Maryland biotechnology community, including state and county officials, for their strong support of our efforts."

About Novavax

Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV).  The company's proprietary virus-like-particle (VLP) technology and single-use bioprocessing system enable rapid vaccine development and production where and when they are needed, worldwide.  The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India.  Additional information about Novavax is available on the company's website: www.novavax.com.

Forward Looking Statements

Statements herein relating to Novavax and its ongoing development of its VLP vaccine products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2010, and filed with the Securities and Exchange Commission. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax to Report First Quarter 2011 Financial Results on May 9, 2011
2. NOVAVAX Announces Release Date of 2010 Year-End Financial Results and Investor Conference Call
3. NOVAVAX to Present at BIT Life Sciences 3rd World Congress of Vaccine
4. Maryland Governor Martin OMalley to Visit Novavax in Celebration of HHS-BARDA Contract Award
5. NOVAVAX to Present at Citi 2011 Global Health Care Conference
6. NOVAVAX to Present at 13th Annual BIO CEO & Investor Conference
7. NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate
8. NOVAVAX Awarded Nearly $1 Million in Grants from IRS Under Qualifying Therapeutic Discovery Project
9. NOVAVAX to Present at the Immunotherapeutics and Vaccine (IMVAC) Summit
10. NOVAVAX Elects Richard H. Douglas to its Board of Directors
11. Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... Philadelphia, PA (PRWEB) , ... October 10, 2017 ... ... University City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. ... accept the award for Excellence in Volunteer Experience from US2020. , US2020’s mission ...
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness Center ... the needs of consumers who are incorporating medical marijuana into their wellness and ... , As operators of two successful Valley dispensaries, The Giving Tree’s two founders, ...
Breaking Biology Technology:
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced Design ... will feature emerging and evolving technology through its ... Summits will run alongside the expo portion of the ... panels and demonstrations focused on trending topics within 3D ... design and manufacturing event will take place June 13-15, 2017 ...
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
Breaking Biology News(10 mins):